Steven Chance for Oxford Brain Diagnostics, Ltd
Oxford Brain Diagnostics Ltd
Founded in neuropathological and neuroimaging expertise, the company’s patented Cortical Disarray Measurement (CDM®) technology uses MRI brain scan data to support early and differential diagnosis, track progression, and predict the decline of neurodegenerative diseases. Oxford Brain Diagnostics is committed to assessing brain health based on changes in the cellular structure, supporting drug development, and helping clinicians around the world in their fight to defeat Alzheimer’s and other neurodegenerative diseases. The CDM® software device can be used as an adjunct to other diagnostics evaluations, intended to predict conversion from Mild Cognitive Impairment to Alzheimer’s Disease in patients previously diagnosed with MCI.
Other Presentations
Aevum – Gail Chan, PhD – View
AKScientist – Aarti Kuver, PhD – View
AmyloiDia – Vladana Vukojevic, PhD – View
ASDERA LLC – Knut Wittkowski, PhD – View
BIORCHESTRA Co., Ltd – Branden Ryu, PhD – View
BioTrillion, Inc. – Savan Devani, MS – View
BrainCures – Krzysztof Potempa, PhD – View
BrainTrip – Jurij Dreo, MD – View
Diadem – Simona Piccirella, PhD – View
Generian Pharmaceuticals, Inc. – Toren Finkel, MD, PhD – View
Lauren Sciences LLC – Susan Rosenbaum, JD –View
LumeNeuro – Ron Dennis – View
Marvel Biotechnology – Mark Williams, PhD, MBA – View
Memandis – Nareem Surya – View
MGH/Harvard Medical School – Xudong Huang, PhD – View
Neuropath Therapeutics Limited – Julie Kelly, PhD – View
University of Haifa – Nathaniel Gould, PhD – View
Winterlight Labs – Nicola Johnson, MS – View